chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Allergic reaction; Headache; Muscle pain; Tired/fatigue; Chills; Nausea and vomiting; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Allergic reaction), HEADACHE (Headache), MYALGIA (Muscle pain), FATIGUE (Tired/fatigue) and CHILLS (Chills) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Mar-2021, the patient experienced HYPERSENSITIVITY (Allergic reaction), HEADACHE (Headache), MYALGIA (Muscle pain), FATIGUE (Tired/fatigue), CHILLS (Chills), NAUSEA (Nausea and vomiting) and VOMITING (Vomiting). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, HYPERSENSITIVITY (Allergic reaction), HEADACHE (Headache), MYALGIA (Muscle pain), FATIGUE (Tired/fatigue), CHILLS (Chills), NAUSEA (Nausea and vomiting) and VOMITING (Vomiting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.
This spontaneous report was received from a physician and refers to a non-pregnant female patient of unknown age. Information on the patient's concurrent conditions, medical history or concomitant therapy was not reported. On an unknown date in 2016 (reported as "last week"), a medical assistant at the physician's office administered a dose of GARDASIL 9 intramuscularly (dose, lot# and expiration date were not reported) to the patient. The primary reporter stated that some of the vaccination ran down the patient's arm and onto her hand, and she was unsure if the patient had received the entire dose of GARDASIL 9. No treatment was given for the event. No adverse effects were reported regarding the patient's skin that came in contact with the vaccine. The primary reporter stated that none of the vaccine came in contact with the medical assistant administering the vaccine. Additional information is not expected as the reporter did not wish to be contacted.
Systemic: Fainting / Unresponsive-Medium, Additional Details: PATIENT FAINTED 20 MINUTES AFTER ADMINISTRATION AND WAS UNRESPONSIVE FOR ABOUT 30 SECONDS. CALLED EMTS WHO RAN A SERIES OF TESTS, DETERMINED PATIENT WAS STABLE. PATIENT REFUSED FURTHER MEDICAL CARE AFTER EVALUATION.
Swelling, inflamation-shoulder to elbow, soreness, itching, time course-2 wks.
The product was refrigerated on 26OCT2021 beyond exiration date 13Oct2021; The patient received expired dose beyind expiratory date 13OCT2021; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The patient received expired dose beyind expiratory date 13OCT2021) and PRODUCT STORAGE ERROR (The product was refrigerated on 26OCT2021 beyond exiration date 13Oct2021) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (The patient received expired dose beyind expiratory date 13OCT2021). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The product was refrigerated on 26OCT2021 beyond exiration date 13Oct2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (The patient received expired dose beyind expiratory date 13OCT2021) and PRODUCT STORAGE ERROR (The product was refrigerated on 26OCT2021 beyond exiration date 13Oct2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided.  It mentioned that the vial was placed in the refrigerator on 26-Oct-2021, the vial did not undergo any temperature excursion and patient did not experienced any adverse events.  No treatment information was provided.
Days 1-2 I had fever of 101, chills, aches,  diarrhea, headache Days 3-11+ (still not resolved) I have experienced nerve pain though out my body, legs, knees, arms, elbows, shoulders, back , face, chest Feels like I am on fire.  Went to medical center, physician's office 2x's, ER ( when I experienced chest tightness, elevated blood pressure)
No additional AE reported; temp excursion 47.9 degrees Fahrenheit; This spontaneous report has been received from a health care professional (HCP) concerning a 12-month-old female patient. Her concurrent conditions, medical history, drug reactions/allergies, and concomitant medications were not provided.  On 05-DEC-2022, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, in left thigh, lot #W023937, expiration date: 06-DEC-2023, administered intramuscularly for prophylaxis.  The administered dose of the vaccine experienced a temperature excursion (product storage error temperature too high) on 01-DEC-2022. The vaccine administered were stored at temperatures of 47.9 degrees Fahrenheit (storage in clinical practice) for 47 minutes. Digital data logger was involved. No additional adverse event reported.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2301USA001175:
pt vax hepta B. pt ex anxiety, blurred vision, nausea 30 min aft vax. sx remitted
redness half-way down her arm about the size of her palm; looks like bruising; This case was reported by a consumer via call center representative and described the occurrence of erythema of extremities in a 77-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 17th November 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 18th November 2020, 1 days after receiving Shingrix, the patient experienced erythema of extremities and bruising of arm. On an unknown date, the outcome of the erythema of extremities and bruising of arm were recovering/resolving.   The reporter considered the erythema of extremities to be related to Shingrix. It was unknown if the reporter considered the bruising of arm to be related to Shingrix.  Additional details were reported as follows: The patient received the 1st dose of Shingrix and the next day, she experienced redness half-way down her arm about the size of her palm. The patient stated that presently it was starting to resolve and looks like bruising. The reporter did not consent to follow-up and declined to provide her healthcare professional's information.
Fever 105°F ibuprofen, cool cloth on head, Tylenol suppository sent to urgent care
Patient experiencing pain in the neck and left arm. Left arm felt numb. A heating pad was applied to affected area before calling a nurse line that patient's insurance provides was instructed to use cold 1st then alternate with heat.
Systemic: Allergic: Rash Generalized-Medium, Additional Details: Recommened that patient taken diphenhydramine and contact their PCP
5/25/99 c/o axillary numbness, swelling & pain;moderate amount of erythema & marked swelling lt deltoid;some mild tenderness  w/deep palpation;
Having issues breathing by nose; Depressed; He can't eat; Can hardly walk; Joints hurt; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DYSPNOEA (Having issues breathing by nose), DEPRESSED MOOD (Depressed), EATING DISORDER (He can't eat), GAIT DISTURBANCE (Can hardly walk) and ARTHRALGIA (Joints hurt) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (Having issues breathing by nose), DEPRESSED MOOD (Depressed), EATING DISORDER (He can't eat), GAIT DISTURBANCE (Can hardly walk) and ARTHRALGIA (Joints hurt). The patient was treated with ZINC for Adverse event, at an unspecified dose and frequency; VITAMIN D3 for Adverse event, at an unspecified dose and frequency; IBUPROFEN for Adverse event, at an unspecified dose and frequency and ACETAMINOPHEN for Adverse event, at an unspecified dose and frequency. At the time of the report, DYSPNOEA (Having issues breathing by nose) outcome was unknown and DEPRESSED MOOD (Depressed), EATING DISORDER (He can't eat), GAIT DISTURBANCE (Can hardly walk) and ARTHRALGIA (Joints hurt) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) Tested negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       It was also reported that the patient didn't receive the 2nd dose and symptoms haven't gone away.  No Concomitant product use was reported.   Most recent FOLLOW-UP information incorporated above includes: On 01-Jun-2021: Follow-up was received on 02-Jun-2021. Updated gender of the patient and added secondary reporter. Added treatment drugs.Added new events Depressed mood (Depressed), Eating disorder (He can't eat), Gait disturbance (Can hardly walk) and Arthralgia (Joints hurt) and their outcomes.
Rash over arms; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash over arms) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Psoriasis vulgaris.    No Medical History information was reported.   In January 2020, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) 75 milligram twice a day. In 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Jul-2021, the patient experienced RASH (Rash over arms). At the time of the report, RASH (Rash over arms) was resolving.            It was unknown if patient was enrolled in a COVID 19 Vaccine Trial. Concomitant medications were not reported.  No treatment information was provided by the reporter. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Reporter did not allow further contact
Patient vomited 2 minutes after vaccine administration. No other signs or symptoms of severe reaction or illness. No significant crying -> just vomit spontaneously.
Fatigue; Myalgia; Injection site pain; Headache (frontal)/Worsening headache; Joint pain; Chills; Nausea; Vomiting; Worsening headache w/ photophobia; Subjective fever; This is a spontaneous report from a contactable physician (patient). A 41-year-old female non-pregnant patient received her first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number=59267-1000-1 /EH9899), via intramuscular on 28Dec2020 09:45 at single dose on her right arm for Covid-19 immunization. Medical history included psoriasis. The patient had no known allergies. Allergies to medications, food, or other products was none. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and did not receive any other medications within 2 weeks of vaccination. It was reported that 6h after administration on 28Dec2020 16:00, the patient experienced fatigue, myalgia, injection site pain; 10h after (in addition to above) on 28Dec2020, the patient experienced headache (frontal), joint pain, chills and 12-28h after (in addition to above) in Dec2020, the patient experienced nausea, vomiting, worsening headache w/ photophobia, subjective fever, joint pain. The patient was not received any treatment for the adverse event. Prior to vaccination, the patient was not diagnosed with COVID-19, since the vaccination, the patient had not been tested for COVID-19. The outcome of the events was recovering.
Child presented with hives over her trunk and face, also some swelling to her hands and feet. She was wheezing but not labored.
Headache, body aches, chills, intermittent nausea, sweating, and general malaise.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient.  A 60-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 17Sep2022 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 59 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 30Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "IBS" (unspecified if ongoing), notes: other medical history: IBS. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: patient received Paxlovid as COVID 19 Treatment.  Treatment start date: 24Jun2023, treatment stop date: 26Jun2023 lot number: GG5318   The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.
After the shot I experienced severe pain in my arm where the shot was administered which did not cease for 5 days after and felt like it slowly spread into the rest of my arm which lessened but felt uncomfortable for more than 5 days. It felt like my left arm was experiencing muscle spasms and aches from my shoulder down to my pinky. During the night around 8 p.m. I also began to feel the symptoms that were said to be normal after a COVID-19 vaccination such as fever, chills, lethargy, headaches, sweats, and body aches. What I didn't expect and what alerted me the most was what I began to feel at about 6:30 am on the following morning which was the inflammation under my armpits, I'm aware that my lymphatic sacs are located there. They swelled up until I was unable to put my arms to my sides and the discomfort was unbearable, I researched and called walk in clinics for help but I currently do not have insurance and I've been waiting to be approved for health care program. Simultaneously, I started to fill a sharp pain and tingling sensation in my chest around the area where my heart is. I felt a heavy pressure on my chest for several days and the swelling under my arms did not start to lessen for 5 straight days. I'm still feeling some discomfort and slight swelling under my arms and it has now been over a week since I was vaccinated.
SHORTNESS OF BREATH; QUADRICEP MUSCLE PAIN; EXTREME FATIGUE; WHOLE BODY ACHES; CHILLS; This spontaneous report received from a patient concerned a 59 year old female. The patient's weight was 128 pounds, and height was 64 inches. The patient's concurrent conditions included non smoker, and non alcoholic, and other pre-existing medical conditions included no known drug allergies. no drug abuse or illicit drug usage. no pertinent medical information advised by consumer. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 201A21A, and expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 06-APR-2021, the subject experienced whole body aches. On 06-APR-2021, the subject experienced chills. On 06-APR-2021, the subject experienced extreme fatigue. On 07-APR-2021, the subject experienced shortness of breath. On 07-APR-2021, the subject experienced quadricep muscle pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from whole body aches, chills, and extreme fatigue on 07-APR-2021, and had not recovered from quadricep muscle pain, and shortness of breath. This report was non-serious.; Sender's Comments: V0 Medical assessment comment not required as per standard procedure as the case was assessed as non-serious.
sore throat; headache; rash on on the arm that received the injection; arm hurt; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (sore throat), VACCINATION SITE RASH (rash on on the arm that received the injection), VACCINATION SITE PAIN (arm hurt) and HEADACHE (headache) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included HYDROCORTISONE for an unknown indication.    On 11-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, the patient experienced VACCINATION SITE PAIN (arm hurt). On 19-Feb-2021, the patient experienced VACCINATION SITE RASH (rash on on the arm that received the injection). On an unknown date, the patient experienced OROPHARYNGEAL PAIN (sore throat) and HEADACHE (headache). At the time of the report, OROPHARYNGEAL PAIN (sore throat), VACCINATION SITE RASH (rash on on the arm that received the injection), VACCINATION SITE PAIN (arm hurt) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not reported.
dizziness; nausea; headache; red 3 inch by 3 inch oval shaped circle at injection site; This spontaneous case was reported by a health care professional and describes the occurrence of DIZZINESS (dizziness), VACCINATION SITE ERYTHEMA (red 3 inch by 3 inch oval shaped circle at injection site), NAUSEA (nausea) and HEADACHE (headache) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (red 3 inch by 3 inch oval shaped circle at injection site). On 08-Jan-2021, the patient experienced DIZZINESS (dizziness), NAUSEA (nausea) and HEADACHE (headache). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEK) for Adverse event, at an unspecified dose and frequency. At the time of the report, DIZZINESS (dizziness), VACCINATION SITE ERYTHEMA (red 3 inch by 3 inch oval shaped circle at injection site), NAUSEA (nausea) and HEADACHE (headache) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Right joint pain in elbow and shoulder-started about 5-7 days after shot.  Still hurts.  Present always worse sometimes than others. Due to the circumstances of vaccination that generated this VAERS report, the vaccine manufacturer, the lot number, the injection site and the providers name and phone number were not available to us.
Anthrax shot RX W/Redness, Swelling, Pain, Numbness.
Information has been received from a nurse practitioner concerning a 19 year old female with an allergy to penicillin who on 21 Oct 2006 was vaccinated intramuscularly in the left deltoid with the first dose of Gardasil (Lot #653650/0702F).  Concomitant therapy included hormonal contraceptives (unspecified). On 21 Oct 2006 the patient experienced minor redness and swelling at the injection site, which later resolved. On 08 Dec 2006 the patient presented with bacterial vaginosis and had a positive pap smear test for high risk HPV types. It was noted that on an unspecified date in November 2006 and on 09 Dec 2005 the patient's pap smear tests were negative. Subsequently, unspecified medical attention was sought and the patient had not recovered from positive pap smear test. Additional information has been requested.
Pt recv vax on 4/19/99; on 4/21/99 pt exp LA red & painful; tx=Benadryl, cool compress
Dizziness lasting from three days after first dose to four days after second dose (March 21, 2021).  Dizziness stopped a few days before second dose, and then started up again one day after second dose.    Migraine or intense heachaches with dizziness every few days for a month.    Headaches still occurring every three or four days at present (March 29) about every two days, but getting more spread out.  I usually get one headache a month, so this is unusual.
69 expired doses administered; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (69 expired doses administered) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H21B) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (69 expired doses administered). On 10-Jan-2022, EXPIRED PRODUCT ADMINISTERED (69 expired doses administered) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided by the reporter  No treatment information was provided by the reporter